{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:15Z","timestamp":1783161435794,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"DOI":"10.7759\/cureus.46792","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:54:06Z","timestamp":1696949646000},"source":"Crossref","is-referenced-by-count":2,"title":["Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements"],"prefix":"10.7759","author":[{"given":"Kathryn","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bollich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha  A","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris C","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Biliary Tract Cholangiocarcinoma","author":"Garikipati SC","year":"2023","unstructured":"Garikipati SC, Roy P. Biliary Tract Cholangiocarcinoma. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi S","year":"2017","unstructured":"Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017, 67:632-44. 10.1016\/j.jhep.2017.03.026","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113871","article-title":"Pharmacological management of cancer pain: Novel therapeutics","volume":"156","author":"Virgen CG","year":"2022","unstructured":"Virgen CG, Kelkar N, Tran A, et al.. Pharmacological management of cancer pain: Novel therapeutics. Biomed Pharmacother. 2022, 156:113871. 10.1016\/j.biopha.2022.113871","journal-title":"Biomed Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00128-y","article-title":"An overview of current recommendations and options for the management of cancer pain: A comprehensive review","volume":"8","author":"Gress KL","year":"2020","unstructured":"Gress KL, Charipova K, Kaye AD, Viswanath O, Urits I. An overview of current recommendations and options for the management of cancer pain: A comprehensive review. Oncol Ther. 2020, 8:251-9. 10.1007\/s40487-020-00128-y","journal-title":"Oncol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.026","article-title":"Ocular adverse effects of Infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor","volume":"128","author":"Magone MT","year":"2021","unstructured":"Magone MT, Hartley IR, Fitzgibbon E, et al.. Ocular adverse effects of Infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor. Ophthalmology. 2021, 128:624-6. 10.1016\/j.ophtha.2020.08.026","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.02.013","article-title":"Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis","volume":"47","author":"Amit O","year":"2011","unstructured":"Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, Burger HU. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. Eur J Cancer. 2011, 47:1772-8. 10.1016\/j.ejca.2011.02.013","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle M","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, et al.. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021, 6:803-15. 10.1016\/S2468-1253(21)00196-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.020","article-title":"SO-5 efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis","volume":"31","author":"Javle M","year":"2020","unstructured":"Javle M, Sadeghi S, Roychowdhury S, et al.. SO-5 efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis. Ann Oncol. 2020, 31:S219. 10.1016\/j.annonc.2020.04.020","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142690","article-title":"Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma","volume":"14","author":"Du J","year":"2023","unstructured":"Du J, Lv X, Zhang Z, Huang Z, Zhang E. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. Front Immunol. 2023, 14:1142690. 10.3389\/fimmu.2023.1142690","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2018.12.004","article-title":"Cholangiocarcinoma","volume":"99","author":"Khan AS","year":"2019","unstructured":"Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019, 99:315-35. 10.1016\/j.suc.2018.12.004","journal-title":"Surg Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"24","author":"Massarweh NN","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017, 24:10.1177\/1073274817729245","journal-title":"Cancer Control"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2021.11.008","article-title":"Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma","volume":"24","author":"Yamada T","year":"2022","unstructured":"Yamada T, Nakanishi Y, Hayashi H, et al.. Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB (Oxford). 2022, 24:1035-43. 10.1016\/j.hpb.2021.11.008","journal-title":"HPB (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.11-1322","article-title":"The role of K-Ras and P53 in biliary tract carcinoma","volume":"71","author":"Ahmad S","year":"2021","unstructured":"Ahmad S, Badr B, Khan A, Rehman R, Ghias K, Muhammad JS, Khan MR. The role of K-Ras and P53 in biliary tract carcinoma. J Pak Med Assoc. 2021, 71:2378-84. 10.47391\/JPMA.11-1322","journal-title":"J Pak Med Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31827332b0","article-title":"Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification","volume":"37","author":"Akiba J","year":"2013","unstructured":"Akiba J, Nakashima O, Hattori S, et al.. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013, 37:496-505. 10.1097\/PAS.0b013e31827332b0","journal-title":"Am J Surg Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.430","article-title":"Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations","volume":"40","author":"Feng Y","year":"2022","unstructured":"Feng Y, Su W, Oh D, et al.. Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations. JCO. 2022, 40:430. 10.1200\/JCO.2022.40.4_suppl.430","journal-title":"JCO"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff RT","year":"2023","unstructured":"Shroff RT, Guthrie KA, Scott AJ, et al.. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023, 41:LBA490. 10.1200\/JCO.2023.41.4_suppl.LBA490","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.3_suppl.231","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations","volume":"33","author":"Ross JS","year":"2015","unstructured":"Ross JS, Wang K, Catenacci DVT,  et, al.. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol. 2015, 33:231. 10.1200\/jco.2015.33.3_suppl.231","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi S","year":"2018","unstructured":"Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018, 15:95-111. 10.1038\/nrclinonc.2017.157","journal-title":"Nat Rev Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu YM","year":"2013","unstructured":"Wu YM, Su F, Kalyana-Sundaram S, et al.. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013, 3:636-47. 10.1158\/2159-8290.CD-13-0050","journal-title":"Cancer Discov"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai Y","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al.. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014, 59:1427-34. 10.1002\/hep.26890","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.698472","article-title":"A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma","volume":"291","author":"Rizvi S","year":"2016","unstructured":"Rizvi S, Yamada D, Hirsova P, et al..  A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016, 291:8031-47. 10.1074\/jbc.M115.698472","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221115317","article-title":"Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions\/rearrangements","volume":"15","author":"Walden D","year":"2022","unstructured":"Walden D, Eslinger C, Bekaii-Saab T. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions\/rearrangements. Therap Adv Gastroenterol. 2022, 15:10.1177\/17562848221115317","journal-title":"Therap Adv Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.157","article-title":"Matching-adjusted indirect comparison of Futibatinib versus chemotherapy and Pemigatinib in cholangiocarcinoma patients with FGFR2 fusions\/rearrangements","volume":"25","author":"Paine A","year":"2022","unstructured":"Paine A, Thom H, Wacheck V, et al.. Matching-adjusted indirect comparison of Futibatinib versus chemotherapy and Pemigatinib in cholangiocarcinoma patients with FGFR2 fusions\/rearrangements. Value in Health. 2022, 25:S33. 10.1016\/j.jval.2022.09.157","journal-title":"Value in Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: First Approval","volume":"81","author":"Kang C","year":"2021","unstructured":"Kang C. Infigratinib: First Approval. Drugs. 2021, 81:1355-60. 10.1007\/s40265-021-01567-1","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S272208","article-title":"Targeted therapy for advanced or metastatic cholangiocarcinoma: Focus on the clinical potential of Infigratinib","volume":"14","author":"Yu J","year":"2021","unstructured":"Yu J, Mahipal A, Kim R. Targeted therapy for advanced or metastatic cholangiocarcinoma: Focus on the clinical potential of Infigratinib. Onco Targets Ther. 2021, 14:5145-60. 10.2147\/OTT.S272208","journal-title":"Onco Targets Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.7.3408813","article-title":"Infigratinib for cholangiocarcinoma","volume":"58","author":"Sadeghi S","year":"2022","unstructured":"Sadeghi S. Infigratinib for cholangiocarcinoma. Drugs Today (Barc). 2022, 58:327-34. 10.1358\/dot.2022.58.7.3408813","journal-title":"Drugs Today (Barc)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita S","year":"2020","unstructured":"Makawita S, K Abou-Alfa G, Roychowdhury S, et al.. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial. Future Oncol. 2020, 16:2375-84. 10.2217\/fon-2020-0299","journal-title":"Future Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook MA","year":"2020","unstructured":"Krook MA, Lenyo A, Wilberding M, et al.. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020, 19:847-57. 10.1158\/1535-7163.MCT-19-0631","journal-title":"Mol Cancer Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v5.i7.171","article-title":"Chemotherapy for cholangiocarcinoma: An update","volume":"5","author":"Ram\u00edrez-Merino N","year":"2013","unstructured":"Ram\u00edrez-Merino N, Aix SP, Cort\u00e9s-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol. 2013, 5:171-6. 10.4251\/wjgo.v5.i7.171","journal-title":"World J Gastrointest Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini J","year":"2016","unstructured":"Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016, 78:1-12. 10.1007\/s00280-016-3003-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle J","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al.. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362:1273-81. 10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study","volume":"101","author":"Valle JW","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, et al.. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009, 101:621-7. 10.1038\/sj.bjc.6605211","journal-title":"Br J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233929","article-title":"Inhibitors in cholangiocarcinoma-a novel yet primary approach: where do we stand now and where to head next in targeting this axis?","volume":"11","author":"Chmiel P","year":"2022","unstructured":"Chmiel P, G\u0119ca K, Rawicz-Pruszy\u0144ski K, Polkowski WP, Sk\u00f3rzewska M. Inhibitors in cholangiocarcinoma-a novel yet primary approach: where do we stand now and where to head next in targeting this axis?. Cells. 2022, 11:3929. 10.3390\/cells11233929","journal-title":"Cells"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al.. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21:671-84. 10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal L","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al.. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023, 388:228-39. 10.1056\/NEJMoa2206834","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182372-infigratinib-for-the-treatment-of-metastatic-or-locally-advanced-cholangiocarcinoma-with-known-fgfr2-gene-fusions-or-rearrangements","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:40Z","timestamp":1707509440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182372-infigratinib-for-the-treatment-of-metastatic-or-locally-advanced-cholangiocarcinoma-with-known-fgfr2-gene-fusions-or-rearrangements"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.46792","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}